Development of proteasome inhibitors in oncology and autoimmune diseases

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• The proteasome regulates intracellular protein degradation, impacting cancer cell growth and immune signaling.
• Bortezomib validated the proteasome as a therapeutic target in oncology, approved for multiple myeloma in 2003.

Purpose of the Study:

• To review next-generation proteasome inhibitors in oncology.
• To discuss their chemical properties, preclinical antitumor activities, and early clinical trials.
• To explore the potential of proteasome inhibitors in autoimmune diseases.

Main Methods:

• Literature review of proteasome inhibitors.
• Analysis of chemical properties.
• Evaluation of preclinical antitumor data.
• Review of early-phase clinical trial results.

Main Results:

• Several distinct proteasome inhibitors have advanced to clinical development.
• Preclinical data demonstrate significant antitumor activities.
• Early clinical trials are evaluating safety and efficacy.

Conclusions:

• Next-generation proteasome inhibitors represent a growing area of cancer therapy.
• Further research is warranted to optimize their use in oncology.
• Potential applications in autoimmune indications are being explored.